CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| Greenstone Biosciences, Inc. |
Paul D Pang |
Tool Translational Research Projects |
Cell Villages and Clinical Trial in a Dish with Pooled iPSC-CMs for Drug Discovery |
$1,350,000 |
| Organos, Inc. |
Samuel Wall |
Tool Translational Research Projects |
Human iPSC-derived micro-heart muscles for high-throughput cardiac drug discovery |
$1,119,382 |
| Stanford University |
Dr. Joseph C. Wu |
Tool Translational Research Projects |
A Novel, Robust and Comprehensive Predictive Tool Using Human Disease-Specific Induced Pluripotent Stem Cells for Preclinical Drug Screening |
$975,000 |
| University of California, Davis |
Aijun Wang PhD |
Medical Device Translational Research Projects |
Living Synthetic Vascular Grafts with Renewable Endothelium |
$3,082,579 |
| Cedars-Sinai Medical Center |
Yuan Yuan |
Diagnostic Translational Research Projects |
A Rapid Clinical Digital Patient-derived Organoid to Guide Breast Cancer Treatment Decision |
$1,535,375 |
| University of California, San Francisco |
Dr. Steven Mack PhD |
Diagnostic Translational Research Projects |
Development of a Noninvasive Prenatal Test for Beta-Hemoglobinopathies for Earlier Stem Cell Therapeutic Interventions |
$633,014 |
| UCSF Benioff Children’s Hospital Oakland |
Dr. Henry A. Erlich Ph.D. |
Diagnostic Translational Research Projects |
Development of a Noninvasive Prenatal Test for Beta-Hemoglobinopathies for Earlier Stem Cell Therapeutic Interventions |
$1,074,177 |
| Stanford University |
Sergiu P Pasca |
Therapeutic Translational Research Projects |
A targeted antisense oligonucleotide therapeutic strategy for Timothy syndrome |
$5,596,629 |
| University of California, Irvine |
Dr. Michael Demetriou |
Therapeutic Translational Research Projects |
GlyTR2 CAR T cell translation: safe pan-cancer killing via velcro-like density-dependent targeting of cancer glycans |
$4,581,144 |
| University of California, San Francisco |
Gregory Maness Allen |
Therapeutic Translational Research Projects |
FM-IL2 CAR T cells for Pancreatic Cancer |
$5,644,776 |
| Entos Pharmaceuticals |
John Lewis |
Therapeutic Translational Research Projects |
Lep001 – gene therapy for the treatment of congenital lipodystrophy |
$4,000,000 |
| Fate Therapeutics, Inc. |
Martin Hosking |
Therapeutic Translational Research Projects |
Development of an off-the-shelf iPSC derived CAR T cell therapy for the treatment of solid tumors |
$4,000,000 |
| Navega Therapeutics |
Ana Maria Moreno |
Therapeutic Translational Research Projects |
Development of an AAV Epigenetic Gene Therapy for Gain-of-Function SCN9A Disorders and Chronic Pain |
$2,525,000 |
| University of California, Los Angeles |
Roger Hollis |
Therapeutic Translational Research Projects |
Evaluation of an ex vivo lentiviral gene therapy for the treatment of Angelman syndrome |
$5,276,765 |
| ReviR Therapeutics |
Dr Paul R August |
Therapeutic Translational Research Projects |
Genetic Therapy Targeting mHTT mRNA and Somatic Expansion to Treat Huntington’s Disease |
$4,618,687 |
| University of Southern California |
David D. Tran |
Therapeutic Translational Research Projects |
A Novel Gene Therapy to Target Glioblastoma via Custom-Engineered Adenovirus-Associated Viral Vectors |
$5,927,454 |
| Nysno Bio |
Jennifer Johnston |
Therapeutic Translational Research Projects |
Parkin Gene Therapy for Parkinson’s Disease |
$2,450,510 |
| Maro Bio |
Akanksha Chhabra |
Therapeutic Translational Research Projects |
A novel non-genotoxic antibody conditioning therapeutic to expand access to and safety of HSCT and CD34+ gene therapies |
$4,043,427 |
| University of California, Los Angeles |
Dr. Donald B. Kohn |
Therapeutic Translational Research Projects |
Hematopoietic Stem Cell Gene Therapy for Alpha Thalassemia |
$5,028,351 |
| Neurona Therapeutics |
Dr. Cory R Nicholas |
Therapeutic Translational Research Projects |
Development of a universal allogeneic human interneuron cell therapy candidate for the treatment of drug resistant focal epilepsy. |
$3,828,714 |
| City of Hope, Beckman Research Institute |
Dr. Lian Tian |
Therapeutic Translational Research Projects |
Targeting pancreatic cancer with Allogeneic Off-the-Shelf PSCA-CAR NK cells |
$0 |
| University of California, Los Angeles |
Dr. Lili Yang |
Therapeutic Translational Research Projects |
Combating Ovarian Cancer with Stem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy |
$5,601,600 |
| Stanford University |
Natalia Gomez-Ospina |
Therapeutic Translational Research Projects |
Toward a Cure for Gaucher Disease Type 1: Autologous Transplantation of Genome Edited Hematopoietic Stem Cells |
$4,696,296 |
| Replay Holdings, Inc. |
Anthony Conway |
Therapeutic Translational Research Projects |
Hypoimmunogenic iPSC-derived TCR-NK cells for oncology |
$0 |
| AcuraStem Incorporated |
Mr. Samuel V. Alworth MS, MBA |
Therapeutic Translational Research Projects |
Development of AS-241, an UNC13A Targeting Antisense Oligonucleotide (ASO) Treatment for ALS, for IND-enabling Studies |
$4,012,325 |
| Axent Biosciences Inc. |
Rocio Sampayo |
Therapeutic Translational Research Projects |
A high quality, accessible cell therapy for Parkinson’s Disease produced in a scalable bioreactor system for 3D cell expansion and differentiation |
$3,999,241 |
| University of California, Los Angeles |
Dr. Gerald Lipshutz |
Therapeutic Translational Research Projects |
Development of a Gene Therapy for Treatment of Guanidinoacetate Methyltransferase Deficiency-Translating In Vivo Proof of Concept to Support a Pre-IND |
$5,145,825 |
| Ray Therapeutics, INC |
Paul Bresge |
Therapeutic Translational Research Projects |
Optogenetic Therapy for Treatment of Geographic Atrophy |
$3,998,930 |
| University of California, San Francisco |
Dr. Sarah Monica Knox |
Therapeutic Translational Research Projects |
Neurogenic hydrogel stimulation of stem cells to regenerate radiation-damaged salivary glands |
$2,312,021 |
| Siren Biotechnology, Inc. |
Dr Nicole K Paulk |
Therapeutic Translational Research Projects |
Development of an AAV gene therapy immunotherapy for the treatment of glioblastoma |
$3,997,919 |
| Cedars-Sinai Medical Center |
Dr. Ahmed Gamal Ibrahim |
Therapeutic Translational Research Projects |
Noncoding RNA drug TY1 as a therapeutic candidate for scleroderma and systemic sclerosis |
$2,590,224 |
| University of California, San Diego |
Dr Karen Christman |
Therapeutic Translational Research Projects |
Pro-regenerative infusible ECM biomaterial for treating acute myocardial infarction |
$4,353,438 |
| University of California, Los Angeles |
Zulema Romero Garcia |
Therapeutic Translational Research Projects |
Adenine Base Editing for Autologous Hematopoietic Stem Cell Gene Therapy of CD3δ SCID |
$5,966,928 |
| University of California, Los Angeles |
Dr. Caroline Y. Kuo |
Therapeutic Translational Research Projects |
Hematopoietic Stem Cell Gene Editing for X-linked Agammaglobulinemia (XLA) |
$4,304,883 |
| University of California, San Diego |
Dr. Eric D. Adler |
Therapeutic Translational Research Projects |
Ex Vivo Modified Hematopoietic Stem Cells to Treat Danon Disease |
$5,180,389 |
| University of California, Los Angeles |
Dr. Gerald Lipshutz |
Therapeutic Translational Research Projects |
Development of a Gene Therapy for the Treatment of Arginase Deficiency – Translating from Proof of Concept to Support Pre-IND Meeting |
$5,266,504 |
| City of Hope, Beckman Research Institute |
Dr Michael A. Caligiuri |
Therapeutic Translational Research Projects |
Targeting multiple myeloma with BCMA-CAR NK cells expressing a GPRC5D-NKG2D bispecific antibody |
$6,036,001 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent
Cardiovascular Events |
$12,714,480 |
| 4D Molecular Therapeutics, Inc. |
Sara Collins |
Preclinical Stage Projects |
Gene Therapy for Alpha-1 Anti-Trypsin Deficiency |
$5,915,073 |
| AcuraStem Incorporated |
Mr. Samuel V. Alworth MS, MBA |
Preclinical Stage Projects |
Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies |
$7,500,000 |
| Cure Rare Disease |
Dr. Tahseen Mozaffar |
Preclinical Stage Projects |
Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9 |
$7,292,297 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia |
$13,000,000 |
| Savanna Biotherapeutics, Inc. |
Dr. Sunil Gandhi Ph.D |
Preclinical Stage Projects |
Microglia replacement therapy for CSF1R-related Leukoencephalopathy |
$12,993,456 |
| Cedars-Sinai Medical Center |
Dr. David Joseph Lefer |
Preclinical Stage Projects |
TY1 and Semaglutide to Treat Cardiometabolic HFpEF |
$10,571,220 |
| University of California, San Diego |
Dr. Stephanie Cherqui |
Preclinical Stage Projects |
CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia |
$7,423,504 |
| Cedars-Sinai Medical Center |
Dr. Alessandra Ciullo |
Preclinical Stage Projects |
Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy |
$10,419,929 |
| Navega Therapeutics |
Ana Maria Moreno |
Preclinical Stage Projects |
Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders |
$9,486,864 |
| Scripps Health |
Dr. Darryl D. D’Lima |
Preclinical Stage Projects |
Stem Cell-Based Cartilage Tissue Regeneration |
$12,715,000 |
| Stanford University |
Dr. Bertha Chen |
Preclinical Stage Projects |
Autologous iPSC-derived progenitor smooth muscle cells for treatment of urinary incontinence |
$7,275,596 |
| Loma Linda University |
Hisham Abdel-Azim |
CCCE Grant |
Inland Empire and Desert Region CIRM Community Care Center of Excellence |
$9,000,000 |
